Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Receives Additional Notice of Allowance for Novel Prodrugs of Hydrocodone
North Liberty, IA – August 7, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for
Toggle Summary FDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™
Trading of KMPH Common Stock Halted KemPharm Conference Call Today at 6:15 p.m. ET CORALVILLE, Iowa , May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced
Toggle Summary FDA Grants Priority Review to KemPharm for KP201/APAP NDA
If Approved, KP201/APAP Could Become the First Immediate-Release Hydrocodone Combination Product With Abuse-Deterrent Properties CORALVILLE, Iowa , Feb. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that the New Drug Application (NDA) for KP201/APAP, its investigational
Toggle Summary FDA Issues Complete Response Letter for Apadaz™ New Drug Application
CORALVILLE, Iowa , June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response
Toggle Summary KemPharm Added to NASDAQ Biotechnology Index
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index
Toggle Summary KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
Company Targets Second Quarter of 2014 to File NDA As Development Activities Accelerate North Liberty, IA – April 16, 2013 – KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has
Toggle Summary KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa , Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Announces Addition to Leadership Team
Andrew Barrett , Ph.D., appointed Vice President, Scientific Affairs CORALVILLE, Iowa , June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an addition to
Toggle Summary KemPharm Announces Additional Patent Protection for Prodrug Portfolio
US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa , Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
CORALVILLE, Iowa , Feb. 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the closing of $86.25 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under